Wuhan Easy Diagnosis Biomedicine Co.,Ltd. (002932.SZ)

17.50 +0.58 (+3.43%) At close: 03:04PM CST

Wuhan Easy Diagnosis Biomedicine Co.,Ltd.

East Lake Hi-Tech Development Zone
No.388, Gaoxin 2nd Road
Wuhan 430074
China
86 27 6552 3649
https://www.mdeasydiagnosis.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 1,547

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Chen Li Li	Chairman & GM	N/A	N/A	1974
Ms. Wang Ying	Vice Chairman & Deputy GM	N/A	N/A	1974
Mr. Guohui Zhou	Financial Manager	N/A	N/A	1984
Mr. Rui Wang	Deputy GM & Board Secretary	N/A	N/A	1978

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.

Description

Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, manufacture, and sale of in-vitro diagnostic products China and internationally. Its products portfolio includes molecular diagnostic products, such as PCR system, nucleic acid extraction and purification instrument, and sample release reagent; blood gas analyzer; immuno diagnosis, including chemiluminescence immunoassay, fluorescence immunity, and immunoquantitative analyzer; and automatic coagulation analyzer. The company also provides emergency and critical illness information solutions, including software, hardware, and certification consulting services; and third-party medical inspection services. It offers products in the areas of cardiovascular and cerebrovascular diseases, infectious diseases, kidney diseases, diabetes, infectious diseases, prenatal and postnatal care, health examination, thyroid, hormones, blood gas, coagulation, drug metabolism, pathogen detection, etc. Wuhan Easy Diagnosis Biomedicine Co.,Ltd. was founded in 2008 and is based in Wuhan, China.

Corporate governance

Wuhan Easy Diagnosis Biomedicine Co.,Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.